A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia.
Phase of Trial: Phase III
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Insulin aspart/insulin protamine aspart; Insulin detemir
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 24 May 2012 Official title amended as reported by ClinicalTrials.gov.
- 07 Mar 2012 Planned number of patients changed from 1569 to NULL.